Home » Newsletters » BioWorld

BioWorld

Feb. 9, 1994

View Archived Issues

PHARMOS COMPLETES PHASE II TRIAL OF GLAUCOMA DRUG

IMMUNOGEN'S UNDERWRITERS EXERCISE OPTION

SPECTRAL LICENSES CDNA CLONES

CARRINGTON EXPANDS WOUND DRESSING LINE

PANEL SAYS THROMBOLYTICS ARE UNDERUTILIZED

FDA RELEASES BST LABELING GUIDELINES

ONCOGENE INKS PACT TO DEVELOP LEAD COMPOUNDS

PHARMOS COMPLETES PHASE II TRIAL

PRICE CONTROLS DRAW CRITICISM

SIGNAL RAISES $6.1M IN FIRST VENTURE ROUND

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for April 28, 2026.
Detecting the invisible: minimal residual disease at AACR 2026
BioWorld Science
Minimal residual disease (MRD) has become a central concept in modern oncology, reshaping how clinicians evaluate response, relapse risk and treatment precision....
News in brief
BioWorld Asia
BioWorld Asia briefs for April 28, 2026
Grace Therapeutics hits CRL setback with GTx-104 despite positive trial
BioWorld
Grace Therapeutics Inc.’s hopes of becoming the first company in decades to update the standard of care in aneurysmal subarachnoid hemorrhage were delayed after...
Sichuan Kelun Pharmaceutical Research Institute discovers GPR6 inverse agonists
BioWorld Science
Sichuan Kelun Pharmaceutical Research Institute Co. Ltd. has identified G protein-coupled receptor 6 (GPR6) inverse agonists reported to be useful for the...